Credit Industriel ET Commercial Purchases 5,000 Shares of Roivant Sciences Ltd. $ROIV

Credit Industriel ET Commercial increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 3.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 155,000 shares of the company’s stock after purchasing an additional 5,000 shares during the period. Credit Industriel ET Commercial’s holdings in Roivant Sciences were worth $1,747,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. boosted its holdings in shares of Roivant Sciences by 3.8% during the 1st quarter. Invesco Ltd. now owns 9,880,526 shares of the company’s stock valued at $99,695,000 after buying an additional 365,468 shares in the last quarter. BlackBarn Capital Partners LP increased its stake in shares of Roivant Sciences by 15.2% in the 1st quarter. BlackBarn Capital Partners LP now owns 4,750,000 shares of the company’s stock worth $47,928,000 after acquiring an additional 625,000 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Roivant Sciences by 12.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,506,400 shares of the company’s stock valued at $50,787,000 after acquiring an additional 506,219 shares during the period. Nuveen LLC purchased a new position in Roivant Sciences during the 1st quarter valued at about $31,988,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Roivant Sciences by 1.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,847,625 shares of the company’s stock worth $28,733,000 after acquiring an additional 35,123 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 0.2%

Roivant Sciences stock opened at $20.62 on Friday. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $20.77. The stock has a fifty day simple moving average of $16.16 and a two-hundred day simple moving average of $12.99. The firm has a market cap of $14.08 billion, a price-to-earnings ratio of -29.46 and a beta of 1.23.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Citigroup raised their target price on shares of Roivant Sciences from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. HC Wainwright boosted their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. JPMorgan Chase & Co. raised their price objective on Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. Jefferies Financial Group lifted their price objective on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Finally, The Goldman Sachs Group boosted their target price on Roivant Sciences from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $21.06.

Insider Buying and Selling

In related news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $20.22, for a total value of $4,044,000.00. Following the completion of the sale, the chief executive officer directly owned 1,504,959 shares in the company, valued at approximately $30,430,270.98. This trade represents a 11.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 5,428,958 shares of company stock valued at $80,491,638. 10.80% of the stock is currently owned by company insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.